Published: 13. November, 2025
The Company has advanced well with its planned activities Closing the clinical and regulatory…
The Company has advanced well with its planned activities
Closing the clinical and regulatory activities related to the CT001 program
Organisational development, search for key competences
Launch and supply planning with commercial partners
US manufacturing technology transfer completed (in October Q4)
Comments from CEO, Jes Trygved: “Building on our recent operational and regulatory progress, we have during third quarter closed the clinical activities for CT001 and completed the US manufacturing tech transfer in October (Q4). We are sharpening our organisational capabilities through a focused search for key competences, and we have initiated launch and supply planning with our commercial partners to support the next phase of CT001. Much of our efforts and current planning is still focused on upcoming US activities which will hopefully make a great impact. Thanks for a great effort by the team!
Link to Report: Q3-2025 Report
